Τίτλος:
Encephalitis in a patient with melanoma treated with immune checkpoint inhibitors: Case presentation and review of the literature
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
After the approval of immune checkpoint inhibitors for the treatment of many solid tumors, a new class of adverse events was recognized through the augmented activation of T cells, known as immune-related toxicities (immune-related adverse events). Encephalitis as an immune-mediated phenomenon is extremely rare, but potentially fatal, and questions remain with regard to its optimal management. Herein, we describe a patient with metastatic melanoma who developed autoimmune encephalitis following treatment with nivolumab plus ipilimumab and present the data concerning clinical features, diagnostic procedure, and therapeutic management of neurological immune-related adverse events. Early recognition and management, and high doses of immunosuppressive agents are the proposed essential strategies for patients' recovery. As immune-related toxicities may represent a clinical biomarker for cancer response to immune checkpoint inhibitors, these adverse events should promptly be managed to ensure that patients will experience the benefits of cancer immunotherapy. © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Συγγραφείς:
Gkoufa, A.
Gogas, H.
Diamantopoulos, P.T.
Ziogas, D.C.
Psichogiou, M.
Περιοδικό:
Journal of Immunotherapy
Εκδότης:
Lippincott Williams and Wilkins
Λέξεις-κλειδιά:
aciclovir; ampicillin; C reactive protein; cobimetinib; corticosteroid; ethambutol; ipilimumab; isoniazid; methylprednisolone; nivolumab; prednisolone; pyrazinamide; rifampicin; vemurafenib; antineoplastic agent; biological marker, acute kidney failure; adult; allergic encephalitis; cancer immunotherapy; case report; cerebrospinal fluid; clinical article; clinical feature; drug efficacy; drug safety; drug tolerability; drug withdrawal; erythrocyte sedimentation rate; fever; human; lumbar puncture; male; metastatic melanoma; middle aged; Mini Mental State Examination; nuclear magnetic resonance imaging; personal experience; physical examination; priority journal; rash; Review; stupor; administration and dosage; adverse event; cancer staging; clinical decision making; complication; disease management; disease predisposition; encephalitis; melanoma; metastasis, Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Decision-Making; Disease Management; Disease Susceptibility; Encephalitis; Humans; Immune Checkpoint Inhibitors; Melanoma; Neoplasm Metastasis; Neoplasm Staging
DOI:
10.1097/CJI.0000000000000326
